Product Description
Injectable THDBH120 is a glucagon-like peptide-1 (GLP-1) receptor and glucose-insulin-promoting polypeptide (GIP) receptor dual-target agonist. It integrates the two insulin-promoting effects of GLP-1 and GIP into a single polypeptide monomolecule, further enhances metabolic stability through molecular design, and performs synergistically promoted functions such as blood sugar control, weight loss, and lipid metabolism to meet the clinical needs of diabetics with poor treatment effects of single-molecule targets or compound formulations. It is expected to become a more long-term treatment for diabetes and obesity medicines. (Sourced from: https://www.moomoo.com/news/post/37029174/tonghua-dongbao-600867-sh-glp-1-gip-dual-target-receptor?level=1&data_ticket=1718216755827869)
Mechanisms of Action: GLP-1 Agonist,GIP Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Type 2 Diabetes|Overweight
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20241940 | P1 |
Unknown |
Type 2 Diabetes |
None |
|
| CTR20234041 | P1 |
Unknown Status |
Type 2 Diabetes |
None |
|
| CTR20242389 | P1 |
Unknown |
Overweight |
None |